Search results for "hyperglycaemia"

showing 8 items of 8 documents

Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis

2010

The ADA and the EASD recently published a consensus statement for the medical management of hyperglycaemia in patients with type 2 diabetes. The authors advocate initial treatment with metformin monotherapy and lifestyle modification, followed by addition of basal insulin or a sulfonylurea if glycaemic goals are not met (tier 1 recommendations). All other glucose-lowering therapies are relegated to a secondary (tier 2) status and only recommended for selected clinical settings. In our view, this algorithm does not offer physicians and patients the appropriate selection of options to individualise and optimise care with a view to sustained control of blood glucose and reduction both of diabe…

cardiovascular riskGlucose-lowering therapyEndocrinology Diabetes and MetabolismeducationSocieties Medical/standardsMEDLINE10265 Clinic for Endocrinology and DiabetologyHypoglycemic Agents/therapeutic use610 Medicine & healthType 2 diabetesHyperglycemia/drug therapyLifestyle modificationRisk FactorsDiabetes mellitusTier 2 networkADA Consensus StatementmedicineInternal MedicineInitial treatmentHyperglycaemiaHumansIn patientFor Debatealgorithmbusiness.industrynutritional and metabolic diseasesType 2 diabetesmedicine.diseaseCardiovascular riskUnited StatesMetforminEASD consensus statementglucose-lowering therapyAlgorithmEurope2712 Endocrinology Diabetes and Metabolism2724 Internal Medicine*AlgorithmsDiabetes Mellitus Type 2/complications/*drug therapytype 2 diabetesbusinessAlgorithmCardiovascular Diseases/prevention & controlhyperglycaemiamedicine.drug
researchProduct

Early prediction of pancreatic cancer from new-onset diabetes: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)…

2021

Pancreatic cancer (PC) is a common cause of cancer-related death, due to difficulties in detecting early-stage disease, to its aggressive behaviour, and to poor response to systemic therapy. Therefore, developing strategies for early diagnosis of resectable PC is critical for improving survival. Diabetes mellitus is another major public health problem worldwide. Furthermore, diabetes can represent both a risk factor and a consequence of PC: nowadays, the relationship between these two diseases is considered a high priority for research. New-onset diabetes can be an early manifestation of PC, especially in a thin adult without a family history of diabetes. However, even if targeted screening…

Cancer Researchmedicine.medical_specialtyConsensusReviewDiseaseMedical OncologySystemic therapyNOconsensus; diabetes; early diagnosis; hyperglycaemia; pancreatic carcinoma; Consensus; Humans; Medical Oncology; Diabetes Mellitus; Pancreatic Neoplasms; PhysiciansDiabetes mellitusPancreatic cancerPhysiciansmedicineDiabetes MellitusHumansFamily historyRisk factorLS4_3Intensive care medicinediabetes pancreatic carcinoma early diagnosis consensus hyperglycaemiadiabetespancreatic carcinomabusiness.industryPublic healthmedicine.diseasePancreatic NeoplasmsOncologyPosition paperbusinesshyperglycaemiaearly diagnosis
researchProduct

The Role of the α Cell in the Pathogenesis of Diabetes: A World beyond the Mirror

2021

Type 2 Diabetes Mellitus (T2DM) is one of the most prevalent chronic metabolic disorders, and insulin has been placed at the epicentre of its pathophysiological basis. However, the involvement of impaired alpha (α) cell function has been recognized as playing an essential role in several diseases, since hyperglucagonemia has been evidenced in both Type 1 and T2DM. This phenomenon has been attributed to intra-islet defects, like modifications in pancreatic α cell mass or dysfunction in glucagon’s secretion. Emerging evidence has shown that chronic hyperglycaemia provokes changes in the Langerhans’ islets cytoarchitecture, including α cell hyperplasia, pancreatic beta (β) cell dedifferentiati…

endocrine system diseasesmedicine.medical_treatmentReviewGlucagon-Like Peptide 1Insulin-Secreting CellsHyperglycaemiaBiology (General)SpectroscopyLangerhans’ isletsGlucagon secretionType 2 diabetesGeneral MedicineComputer Science ApplicationsChemistryAutocrine Communicationtype 2 diabeteshormones hormone substitutes and hormone antagonistsmedicine.medical_specialtyendocrine systemQH301-705.5GlucagonCatalysisInorganic ChemistryParacrine signallingInsulin resistanceInternal medicineDiabetes mellitusParacrine CommunicationmedicineAnimalsHumansHypoglycemic AgentsPhysical and Theoretical ChemistryQD1-999Molecular BiologyDipeptidyl-Peptidase IV Inhibitorsbusiness.industryInsulinOrganic ChemistryType 2 Diabetes Mellitusmedicine.diseaseGlucagonEndocrinologyDiabetes Mellitus Type 1Diabetes Mellitus Type 2Glucagon-Secreting CellsbusinessHypoglycaemiahyperglycaemiaHyperglucagonemiahypoglycaemiaInternational Journal of Molecular Sciences
researchProduct

Influence of spurious dilution and hyperglycemia on erythrocytes and platelets evaluated with two different hematological analyzers

2015

The integrity of whole blood samples may be compromised by suboptimal collection practices. Therefore, we investigated the influence of spurious hyperglycemia on erythrocytes and platelets, assessed with two hematological analyzers using optical or impedance technique. Three K2EDTA blood specimens were collected from 12 healthy subjects, pooled and divided into four aliquots. The first aliquot was left untreated (glucose concentration 4.4 mmol/L), whereas scalar amounts of standard 5% glucose solution were added to the remaining, generating glucose contamination of 5% (19.2 mmol/L), 10% (33 mmol/L) and 20% (62 mmol/L). Hematological testing was then performed using Siemens Advia 2120 and Sy…

medicine.medical_specialtyHealth Toxicology and MutagenesisBiomedical EngineeringMean corpuscular hemoglobinHematocritGeneral Biochemistry Genetics and Molecular BiologyArtificial IntelligenceInternal medicinemedicinehyperglycaemia erythrocytes plateletsPlateletGeneral Pharmacology Toxicology and PharmaceuticsMean platelet volumeWhole bloodGeneral Immunology and Microbiologymedicine.diagnostic_testMean corpuscular hemoglobin concentrationChemistryGeneral NeuroscienceRed blood cell distribution widthGeneral MedicineEndocrinologyImmunologyplateletserythrocytesHemoglobinGeneral Agricultural and Biological Scienceshyperglycaemia
researchProduct

Melanocortin receptor agonists MCR1-5protect photoreceptors from high-glucose damage and restore antioxidant enzymes in primary retinal cell culture

2016

Retinal photoreceptors are particularly vulnerable to local high-glucose concentrations. Oxidative stress is a risk factor for diabetic retinopathy development. Melanocortin receptors represent a family of G-protein-coupled receptors classified in five subtypes and are expressed in retina. Our previous data indicate that subtypes 1 and 5 receptor agonists exert a protective role on experimental diabetic retinopathy. This study focuses on their role in primary retinal cell cultures in high-glucose concentrations. After eye enucleation from wild-type male C57BL/6 mice, retinal cells were isolated, plated in high-glucose concentration and treated with melanocortin receptors 1 and 5 agonists an…

Male0301 basic medicineOpsinmedicine.medical_specialtyChemokineBlotting WesternPrimary Cell CultureEnzyme-Linked Immunosorbent AssayBiologyNeuroprotection03 medical and health scienceschemistry.chemical_compound0302 clinical medicineMelanocortin receptorInternal medicinemedicineReceptoroxidative streGlutathione PeroxidaseRetinaStaining and LabelingAnimalSuperoxide DismutaseReceptors Melanocortinmelanocortin receptor agonistRetinalCell BiologyphotoreceptorImmunohistochemistryNeuroprotectionprimary retinal cell cultureMice Inbred C57BLGlucoseOpsin030104 developmental biologymedicine.anatomical_structureEndocrinologyGene Expression Regulationchemistrybiology.proteinMolecular MedicineAntioxidantMelanocortinhyperglycaemia030217 neurology & neurosurgeryPhotoreceptor Cells VertebrateJournal of Cellular and Molecular Medicine
researchProduct

Effects of diabetes on the osseointegration of dental implants

2007

The increased prevalence of diabetes mellitus has become a public health problem. Hyperglycaemia entails a rise in the morbidity and mortality of these patients. Although a direct relationship with periodontal disease has already been shown, little is known about the results of dental implants in diabetics. The present paper reviews the bibliography linking the effect of diabetes on the osseointegration of implants and the healing of soft tissue. In experimental models of diabetes, a reduced level of bone-implant contact has been shown, and this can be reversed by means of treatment with insulin. Compared with the general population, a higher failure rate is seen in diabetic patients. Most …

implantimplanteUNESCO::CIENCIAS MÉDICASDiabetes Mellitusosseointegrationoseointegración:CIENCIAS MÉDICAS [UNESCO]hiperglucemiahyperglycaemia
researchProduct

An integrated care pathway for cancer patients with diabetes: A proposal from the Italian experience

2020

Diabetes and cancer frequently coexist in the same subject, often with relevant clinical effects on the management and prognosis of the comorbid patient. The existing guidelines, however, do not appropriately address many clinical issues in this setting. Although collaboration between diabetologists and oncologists should play an important role in achieving appropriate levels of care, close coordination or agreement between these specialists is seldom offered. There is an urgent need for greater interdisciplinary integration between all specialists involved in this setting, for a shared approach ensuring that organisational silos are overcome. To this end, the Italian Associations of Medica…

Glucose controlHospital settingSettore MED/06 - Oncologia MedicaEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismMedical OncologyDiabetes Complications03 medical and health sciences0302 clinical medicineEndocrinologyClinical pathwayClinical pathwaysClinical pathwayDiabetes mellitusNeoplasmsInternal MedicineMedicineHumans030212 general & internal medicineInpatient diabetes careDiabetes and cancerbusiness.industryDelivery of Health Care IntegratedCancerGeneral MedicineInpatient hyperglycaemiamedicine.diseasePrognosisIntegrated careItalyOncologyDischarge planningContinuity of careMedical emergencybusiness
researchProduct

Hydroxychloroquine, COVID ‐19 and diabetes. Why it is a different story

2020

Hydroxychloroquine has been proposed for the cure of the COVID-19 due to its anti-inflammatory and anti-viral action. People with diabetes are more prone to severe outcome if affected by COVID-19 and the use of Hydroxychloroquine might have some benefit in this setting. However, the use of Hydroxychloroquine in diabetes deserves particular attention for its documented hypoglycemic action.

Blood Glucosemedicine.medical_specialty2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)Endocrinology Diabetes and MetabolismSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)MEDLINE030209 endocrinology & metabolismGlycemic Control030204 cardiovascular system & hematologySeverity of Illness IndexDiabetes Complications03 medical and health sciences0302 clinical medicineEndocrinologyCommentariesInternal medicineDiabetes mellitusSeverity of illnessDiabetes MellitusInternal MedicinemedicineHyperglycaemiaHumansHypoglycemic AgentsBlood Glucose COVID-19 Diabetes Complications Diabetes Mellitus Glycemic Control Humans Hydroxychloroquine Hypoglycemic Agents SARS-CoV-2 Severity of Illness Index Signal TransductionSARS-CoV-2business.industryDiabetesCOVID-19Hydroxychloroquinemedicine.diseaseCOVID-19 Drug TreatmentACE2 Cardiovascular disease COVID‐19CommentarybusinessHydroxychloroquineSignal Transductionmedicine.drugDiabetes/Metabolism Research and Reviews
researchProduct